Table 1.
Differences between the pneumococcal polysaccharide and conjugate vaccines
| Polysaccharide vaccine (PPV23) Pneumovax 23® | Conjugate vaccine (PCV13) Prevnar 13® | |
|---|---|---|
| Immunogenic in children aged <2 years | No | Yes |
| Stimulation of T-cell immunity | No | Yes* |
| Induction of immunological memory | No | Yes* |
| Induction of mucosal immunity | No | Yes* |
| Effect on nasopharyngeal carriage | No | Yes* |
| Included serotypes | 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9 V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F | 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 23F |
| Percentage of IPD cases with vaccine serotype in Norway in 2013 | 72% | 39% |
| Antigen concentration (purified capsular polysaccharide) | 25 μg of each of the 23 serotypes | 2·2 μg of each serotype, except for serotype 6B: 4·4 μg |
| Adjuvants | None | Aluminium phosphate |
IPD, Invasive pneumococcal disease.
Serotypes in bold indicate serotypes that are only included in the respective vaccine.
*
Shown in children. Not yet known if this also accounts for adults.